focus -WSS

focus

author：Wikipedia 2025-10-06 10:47:01 - browse：8

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： FDA reorg will put new emphasis on investigations, sources say

hotspot

WSS

FDA reorg will put new emphasis on investigations, sources say

Readout Newsletter: Zepbound, Valneva's vaccine, and more

What health policies could hitch a ride on a spending bill?

What is STAT's opinion section for?

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Cancer diagnosis changes perspective doctor, former hospital CEO

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Tori Bowie and the unacceptable rates of Black maternal death

What health policies could hitch a ride on a spending bill?

Cancer drug shortages should be causing more outrage

A letter from the executive editor: STAT UnitedHealth investigation

The cancer drug shortage isn’t new — and neither are the solutions

After decades in use, heart stents finally beat placebo

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

hotspot

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Experimental asthma app from Apple and Anthem shows promise

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Today's health inequities arise from racist U.S. history, say experts

Healthy food access boosts outcomes in two studies

After decades in use, heart stents finally beat placebo

knowledge

hotspot

focus

focus